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BACKGROUND: Mortality from COVID-19 is high among hospitalized patients and effective 
therapeutics are lacking. Hypercoagulability, thrombosis and hyperinflammation occur in 
COVID-19 and may contribute to severe complications. Therapeutic anticoagulation may 
improve clinical outcomes through anti-thrombotic, anti-inflammatory, and anti-viral 
mechanisms.  
PRIMARY OBJECTIVE: To evaluate whether therapeutic-dose anticoagulation with low 
molecular weight heparin (LMWH) or unfractionated heparin (UFH) prevents mechanical 
ventilation and/or death in patients hospitalized with COVID-19 compared to usual care. 
STUDY DESIGN: An international, open-label, adaptive randomized controlled trial. Using a 
Bayesian framework, the trial will declare results as soon as pre-specified posterior probabilities 
for either superiority, futility, or harm are reached. The trial uses response-adaptive 
randomization to maximize the probability that patients will receive the more beneficial 
treatment approach, as treatment effect information accumulates within the trial. By leveraging a 
common data safety monitoring board and pooling data with a second similar international 
Bayesian adaptive trial (REMAP-COVID anticoagulation domain), treatment efficacy and safety 
will be evaluated as efficiently as possible. 
PRIMARY OUTCOME: The primary outcome is an ordinal endpoint with three possible 
outcomes based on the worst status of each patient through day 30: no requirement for invasive 
mechanical ventilation, invasive mechanical ventilation, or death.  
FEASIBILTY AND SIGNIFICANCE: Using an adaptive trial design, the ATTACC trial will 
establish whether therapeutic anticoagulation can reduce mortality and/or avoid the need for 
mechanical ventilation in patients hospitalized with COVID-19.  Leveraging existing networks to 
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recruit sites will increase enrollment and mitigate enrollment risk in sites with declining COVID-
19 cases. 
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INTRODUCTION 
 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a novel coronavirus 
that has rapidly spread across the globe causing severe respiratory infection.1,2 With the possible 
exception of remdesivir, no therapies have proven efficacy.3,4 Rapidly-deployable, safe and 
effective therapeutic agents are urgently needed. Coronavirus disease 2019 (COVID-19) is 
associated with activation of coagulation and inflammatory pathways (Figure 1), suggesting that 
therapeutic-dose anticoagulation may improve clinical outcomes. 
 Early observational reports suggest that that COVID-19 infection is associated with 
hypercoagulability and increased risk of thrombosis.5-7 Thrombosis is closely linked to 
systematic vascular inflammation and, distinct from other respiratory viral syndromes, COVID-
19 appears to be associated with a profound endotheliopathy.8 D-dimer levels may signal this 
coagulopathy and predict poor prognosis.5,9,10 D-dimers may also help identify patients most 
likely to benefit from anticoagulation. 
 Heparin is a commonly used anti-thrombotic agent that facilitates antithrombin-mediated 
inactivation of factors Xa and IIa. Heparin has diverse anti-inflammatory properties and is 
known to inhibit complement and adhesion molecule expression in the microvasculature,11 and 
down-regulate IL-6.12 Heparin may also exert direct anti-viral effects on SARS-CoV-213. Upon 
binding heparin, the SARS-CoV-2 spike protein undergoes conformational changes that interfere 
with binding to angiotensin converting enzyme-2 (ACE2). A similar anti-viral effect of heparin 
has also been observed with SARS-CoV-1.14,15 
 A significant body of evidence including laboratory data11,12, animal models16, 
observational studies17, randomized controlled trials in humans,18,19 and meta-analyses18,20 
support the potential for heparin to reduce mortality in sepsis. Data are limited in COVID-19, 
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although an observational study from China suggested that the use of low-dose heparin may be 
associated with lower mortality in patients with elevated D-dimer levels.21,22 A second 
observational cohort from New York observed that therapeutic anticoagulation was associated 
with longer survival among critically ill patients with COVID-19.23 Both observational studies 
had important limitations and cited the need for randomized trials. 
 These data provide a compelling rationale to evaluate therapeutic anticoagulation with 
heparin in patients with COVID-19. The proposed AntiThrombotic Therapy for Amelioration of 
Complications of COVID-19 (ATTACC) trial will leverage an international network of over 30 




 To establish whether therapeutic-dose parenteral anticoagulation with heparin prevents the 
need for mechanical ventilation and/or death in patients hospitalized with COVID-19. 
 
Trial design 
 We will perform an international, open-label, pragmatic, adaptive randomized controlled 
trial enrolling adult patients hospitalized with confirmed COVID-19 infection.  
 ATTACC employs a Bayesian framework for statistical inference. This framework was 
chosen as it facilitates an adaptive trial design, providing needed flexibility within a rapidly 
evolving pandemic where uncertainty exists surrounding event rates and potential treatment 
effect sizes. The incorporation of response-adaptive randomization (RAR) according to baseline 
D-dimer facilitates allocation of a participant based on their observed probability of benefit 
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within a D-dimer-defined subgroup. In the context of emerging observational evidence 
suggesting potential benefit from therapeutic anticoagulation, RAR is useful to increase 
acceptance of the trial by both clinicians and patients given that patients have a higher 
probability of receiving therapeutic anticoagulation if there is early evidence of benefit in 
specific D-dimer subgroups. 
 
Trial interventions 
Intervention group: The active treatment arm will receive therapeutic-dose parenteral 
anticoagulation with either low molecular weight heparin (LWMH) or unfractionated heparin 
(UFH) at doses for the treatment of venous thromboembolism (VTE). Therapeutic 
anticoagulation will be continued for up to 14 days or until recovery (defined as hospital 
discharge or liberation from supplemental oxygen for >24 hours if oxygen was initially 
required), whichever comes first. The intervention arm is designed to be accessible, flexible and 
pragmatic. Heparin is an inexpensive drug that is accessible to practitioners in health systems 
around the world. The specific heparin formulation, decisions pertaining to anticoagulation 
monitoring, dosing, and dose adjustments will be conducted according to local practice. The 
choice of therapeutic (as opposed to intermediate) dose heparin is supported by observational 
studies of heparin in sepsis17, and is associated with low bleeding rates24. Therapeutic dosing is 
required to provide separation between groups, especially given the heterogenous 
thromboprophylactic strategies employed in the care of patients with COVID-1923.  
 
Control group: The control arm will receive usual care that may include pharmacologic 
thromboprophylaxis (e.g., low dose LMWH or UFH) according to local practice. In some 
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centers, intermediate doses of LMWH or UFH for venous thromboprophylaxis are used, but 
remain below the therapeutic doses used in ATTACC; local practice may vary by center and 
over time, but will be recorded. 
 
Co-enrollment 
 As anticoagulation is anticipated to be an ancillary supportive care strategy in patients with 
COVID-19, co-enrollment is permitted provided the co-enrolling trials are not evaluating 
anticoagulants or anti-platelet medications. This is intended to encourage the efficient conduct of 
alternative therapeutic trials in patients with COVID-19. Interactions with other potential 
COVID-19 therapies are not expected a priori, but will be explored post hoc. 
 
Patient selection  
Inclusion criteria: Patients ≥18 years of age admitted to hospital with laboratory-confirmed 
COVID-19. The anticipated duration of hospitalization must be >72 hours from randomization, 
and patients must be enrolled within 72 hours of hospital admission or confirmation of COVID-
19. 
 
Exclusion criteria: Major exclusions include invasive mechanical ventilation at the time of 
randomization, active bleeding, or risk factors for bleeding. The complete list of the exclusion 
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Primary outcome: The primary outcome is an ordinal categorical endpoint with three possible 
outcomes based on the worst status of each patient through day 30: no invasive mechanical 
ventilation, invasive mechanical ventilation, or death. This end-point was chosen because (a) 
invasive mechanical ventilation and death are clinically relevant outcomes with high importance 
to patients and healthcare systems; (b) the ordinal endpoint increases statistical power in 
comparison to a binary endpoint and is justified based on the clinical importance; and (c) the risk 
of ascertainment bias is low with this endpoint focused on objectively definable events. Venous 
thromboembolism (VTE) was not included in the primary outcome due to concerns for 
ascertainment bias, as patients on therapeutic anticoagulation may be less likely to receive 
imaging, which would therefore favor the intervention arm. Similarly, myocardial infarction 
(MI) was not included in the primary outcome as cardiac injury in COVID-19 patients can result 
from a variety of mechanisms, and it’s unclear how or if heparin affects this. Both VTE and MI 
are captured as secondary outcomes. 
 
Secondary outcomes: The following safety and efficacy outcomes will be assessed:  
Safety: The two major safety concerns associated with heparin anticoagulation relate to major 
bleeding and heparin induced thrombocytopenia (HIT).25 As such, our safety outcomes include 
laboratory confirmed HIT, and major bleeding defined according to the International Society on 
Thrombosis and Haemostasis (ISTH).26 This definition includes fatal bleeding, symptomatic 
bleeding in a critical area or organ (such as intracranial, intraspinal, intraocular, retroperitoneal, 
intraarticular, pericardial, or intramuscular with compartment syndrome), bleeding causing a fall 
in hemoglobin of ≥2 g/dL, or leading to the transfusion of 2 or more whole blood or red cell 
units. The presence of HIT and/or major bleeding will be assessed on days 1, 3, 7, 14 and 21.  
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Efficacy: [Assessed at 21 days]: organ support-free days (days alive and without the need for 
invasive or non-invasive mechanical ventilation, high flow nasal cannula at ≥30 L/min flow, or 
vasopressor support); [Assessed at 30 days]: use of non-invasive ventilation or high-flow nasal 
cannula, intubation, ventilator-free days, ICU-free days, hospital-free days. For outcomes with 
“free-days” assessed at 21, 30 or 90 days, patients will be assigned a value of -1 if they die 
before 21, 30, or 90 days, respectively. [Assessed at 30 and 90 days]: VTE, myocardial 
infarction, ischemic stroke, and all-cause mortality.  
 
Recruitment and patient consent 
 In response to pandemic-related infection control measures and policies that encourage the 
avoidance of unnecessary direct person-to-person contact, modifications to traditional written 
informed consent are required. Consent will be obtained as per Institutional Research Ethics 
Board / Institutional Review Board and FDA recommendations, but is anticipated to include 
verbal consent and consent obtained by telephone from either the patient or their designated 
substitute decision maker.  
 
Methods of data collection, and the duration of follow-up 
 To maximize the operational feasibility of the trial, following randomization, collected data 
includes variables typically part of routine care. Laboratory investigations are not mandated, but 
will be ascertained using an electronic case report form as per the study schedule (Appendix 1). 
Electronic data collection using an online case report form has been prioritized to minimize 
infectious exposure. Subjects will be followed until hospital discharge or 90-days, whichever 
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comes first. For those discharged before 90 days, telephone contact will be undertaken to 
ascertain the secondary 90-day outcomes.  
 
Concomitant medications: Concomitant medications including proven or experimental COVID-
19 treatments and anti-platelet agents will be collected from time of consent to 14 days or time of 
treatment discontinuation (whichever occurs first). Anticoagulant use following completion of 
the study protocol but prior to the 30-day assessment will also be collected.  
 
Methods to protect against bias 
Randomization and allocation concealment: A web-based, variable-block, randomization system 
will be used to allocate treatment assignments. 
 
Outcome adjudication: The primary outcome will be independently verified by a central events 
adjudication committee. Given the importance of standardized definitions and reporting, major 
hemorrhage and laboratory confirmed HIT will be adjudicated without knowledge of treatment 
assignment. Venous and arterial thrombotic events will be adjudicated using similar methods. 
 
Analytic plan 
Sample size and power calculations: The trial design uses a Bayesian adaptive framework to 
reach a conclusion regarding superiority or futility in an efficient manner within three different 
baseline D-dimer-defined subgroups. D-dimer subgroups will be defined at the first interim 
analysis based on the 50th and 75th percentile values measured in the first 100 patients. The trial 
will enroll until the pre-specified stopping criterion for benefit (>99% posterior probability of 
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proportional odds ratio (OR) >1) or futility (<10% posterior probability of proportional OR>1.2) 
are reached within each D-dimer subgroup. An OR of 1.2 is used as the minimum treatment 
effect threshold to declare futility given it is approximately equivalent to an absolute risk 
reduction in mortality of ≤1% assuming a baseline event rate of 25% for intubation and 12.5% 
for death. We will enroll up to a maximum of 3,000 patients. Trial simulations indicate that the 
risk of Type I error remains below 5% at 3,000 patients and that enrolling 2,000 patients will 
give 90% power to detect an OR ≥ 1.5 for avoiding intubation or death (equivalent to a ≥5% 
absolute risk reduction in mortality). If the treatment is harmful (OR<1), there is a 60% chance 
that the trial will be halted after enrolling 200-300 patients based on the futility stopping 
criterion. Data will be analyzed based on the intention-to-treat principle. 
 
Analysis of primary and secondary outcomes: The primary analysis of the ordered categorical 
endpoint is a cumulative proportional odds model (OR>1 suggests treatment benefit). The effect 
of therapeutic anticoagulation is modeled within prespecified patient subgroups based on the 
baseline D-dimer levels. Each patient is classified by their baseline D-dimer levels as highest 
(top quartile), median (3rd quartile), and lowest (less than median). An additional category will 
be added for patients in whom D-dimer is not available at the time of randomization. Each 
conclusion for therapeutic anticoagulation is by subgroup, with a statistical model that borrows 
the effect across D-dimer subgroups. The baseline risks for each group are modeled with 
independent weak prior distributions with the lowest D-dimer group serving as the reference 
population. 
 In addition to an overall adaptive sample size, the trial also employs response-adaptive 
randomization for the effect of therapeutic anticoagulation within each of these 3 subgroups. 
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Interim analyses will be conducted after every 100 patients enrolled to re-weight allocation 
probabilities based on treatment responses. At each interim analysis, the trial may reach a 
conclusion of superiority or futility within any of the subgroups, which would stop 
randomization in that subgroup. If no conclusion within a subgroup is reached and randomization 
continues, the randomization probabilities will be re-weighted based on posterior probabilities of 
benefit or harm within the subgroup to a maximum of 90%. Post hoc analyses will be performed 
to investigate differential efficacy and safety by sex.  
 
Risks to the safety of potential participants  
 As an open label trial of approved and commonly used drugs with well-established safety 
and side-effect profiles, adverse events and serious adverse events captured in this trial are 
events possibly related to the investigational agent, which includes major bleeding and 
laboratory confirmed HIT.  
 
Study management and governance 
 Given the time sensitive nature of the pandemic, existing international expertise and 
capacity was leveraged to create a trial infrastructure with distributed roles amongst a number of 
academic institutions and organizations. The University of Manitoba (Winnipeg, Canada) is the 
study sponsor, and will support site contracts and payments. The Clinical Coordinating Centre 
(CCC) is Ozmosis@UHN (Toronto, Canada) who will be responsible for overall study 
management. The Data Coordinating Centre (DCC) is SOCAR Research (Nyon, Switzerland), an 
academic Clinical Research Organization in Switzerland. SOCAR will work closely with our 
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trial statistical consultant, Scott Berry (Austin, U.S.A) to prepare response-adaptive 
randomization algorithms and data for frequent interim analyses.  
 The Executive Committee will consist of the Principal Investigators, country leads and 
representatives from the CCC. The Executive Committee is responsible for the execution of the 
trial according the study protocol. A Steering Committee will be responsible for providing 
clinical and methodological guidance, including overall study design, execution, analysis, and 
publication of the main study results.  
   
Data safety monitoring board 
 An independent data safety monitoring board (DMSB) will regularly receive the results of 
interim analyses as well as adverse events and serious adverse events reports.  Based on 
previously described trial conclusion parameters the DSMB may recommend stopping for 
superiority, futility, or harm, of either the entire trial or the a priori defined d-dimer subgroups. 
The DSMB is empowered to report independently to health authorities at their discretion. 
 To minimize the time to trial completion, and to garner robust estimates of safety, the 
ATTACC investigators will combine data with patients enrolled in REMAP-COVID using a 
common external DSMB. REMAP-COVID is a Bayesian adaptive platform trial that is currently 
activating up to 200 sites in the U.S., United Kingdom, and European Union (EU) sites. 
REMAP-COVID represents a sub-platform of the REMAP-CAP (Community Acquired 
Pneumonia) international platform trial that specifically targets COVID-19 patients27. Although 
this trial is operationally separate from ATTACC, the three principal investigators from 
ATTACC serve on the working group for the Therapeutic Anticoagulation domain of REMAP-
COVID (RZ [chair], EG [deputy chair], and PL).  Trial procedures and endpoints have thus been 
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harmonized between REMAP-COVID and ATTACC and the data will be combined to permit 
shared interim analyses in the context of a shared external DMSB.  This innovative and highly 
collaborative data sharing structure permits evidence of efficacy and safety to be realized as 
quickly and as robustly as possible.  
 
Estimated duration of the trial 
 Based on projected enrolment rates (10 patients per month at, initially, 35 centres with 
expansion as needed), we anticipate trial completion within 12 months. The inclusion of patients 
from high volume sites in Canada, U.S., Brazil, and Mexico may shorten this estimate. Given the 
Bayesian adaptive framework of ATTACC, the entire trial or specific subgroups of D-dimer 
patients may be stopped earlier based on the results of interim analyses. Although the maximum 
sample size is 3000 patients, trial simulations indicate a moderately high probability of stopping 
for superiority before this sample size is attained.  
 
Dissemination strategy 
 Results of the trial will be communicated rapidly to public health officials and policy 
makers as well as the general medical community in order to inform urgent pandemic 
management. We will work with our patient partners and knowledge users to prepare and 
disseminate trial results via traditional publications, society recommendations, policy statements, 
media, and social media. Results will be published in open access journals, with study data made 
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 ATTACC has broad international support. In Canada, ATTACC has partnered with the 
Canadian Critical Care Trials Group (CCCTG), the Canadian venous thromboembolism research 
(CanVECTOR) network and the Canadian trials for COVID (CATCO) trial network, a group of 
>50 hospitals participating in anti-viral therapeutic strategies for COVID-19 patients. 
Internationally ATTACC has partnered with REMAP-COVID, an international adaptive 
platform trial that is currently expanding to potentially include over 200 sites in the U.S., United 
Kingdom and EU. ATTACC has also partnered with the Worldwide Network for Innovation in 
Clinical Education and Research (WNICER) network, which includes our centers in Brazil and 
Mexico, and is endorsed by both the International Network of VENous Thromboembolism 
Clinical Research Network (INVENT) and the International Forum of Acute Care Trialists 
(InFACT). ATTACC has partnered with sites in Brazil and Mexico to increase the speed of 
recruitment and the generalizability of findings in low/middle income countries. These 
international partnerships have been developed to permit efficient site recruitment and promote 
swift trial completion in the face of a rapidly evolving pandemic with changing and 
unpredictable case volumes. 
 
DISCUSSION 
 The ATTACC trial has been designed to urgently evaluate if therapeutic anticoagulation 
will benefit hospitalized patients with COVID-19 when compared with usual care. Multiple 
pandemic-specific design elements have been incorporated to promote the rapid recruitment of 
patients, and terminate the trial as soon as a clinically relevant conclusion has been achieved. By 
leveraging existing networks, the ATTACC investigators have further created an international 
network of committed sites with the necessary expertise and infrastructure to advance our 
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understanding of pathophysiologic mechanisms of thrombosis in COVID-19 and evaluate 
antithrombotic strategies to improve clinical outcomes.  
 The use of a Bayesian adaptive trial design is well-suited for the pandemic where limited 
information exists to inform a priori estimates of event rates and effect sizes. Frequent interim 
analyses with the ability to terminate based on clinically important conclusions will allow the 
trial to efficiently determine if heparin is efficacious, while monitoring safety. As an open trial, 
our operational procedures and statistical analyses have been detailed a priori to ensure scientific 
integrity, and reduced bias28.    
 A unique feature of ATTACC is the use of a common external DSMB shared with a second 
similar Bayesian adaptive international trial (REMAP-COVID)27. By harmonizing the two trial 
procedures and outcomes, this innovative and highly collaborative data sharing structure permits 
evidence of efficacy and safety to be realized as quickly and as robustly as possible.  
 The scope of ATTACC and diverse international partnerships have facilitated early 
successes. Content experts from cardiology, hematology, thrombosis, intensive care, medication 
safety and trial methodology have collaborated to design a trial that meets the unique situational 
needs of the COVID-19 pandemic. Given the time-sensitive nature of the pandemic, roles were 
distributed internationally based on the immediate capacity and expertise. Existing trial networks 
were leveraged to recruit sites, which will increase enrollment and also mitigate enrollment risk 
in sites with declining COVID-19 cases. The trial team and infrastructure established creates the 
opportunity to test future hypotheses such as the role of anti-platelet agents, or other therapeutics. 
 ATTACC is planning an ancillary biomarker study and creation of a biobank that will 
advance our understanding of the pathophysiology of COVID-19 infection, the interplay between 
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infection, inflammation and coagulation, and the mechanistic role of heparin. The biobank will 
be leveraged for further research, extending beyond the duration of the trial.  
 In the context of an evolving global pandemic, the ATTACC trial has been designed to 
efficiently address a clinical question of global priority. To launch the trial as quickly as possible 
we chose to evaluate and repurpose an existing, widely accessible, and inexpensive class of 
medications with strong biologic plausibility. If therapeutic anticoagulation is found to be 
superior to usual care, treatment can be rapidly instituted for patients hospitalized with COVID-
19 around the world.   
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Table 1. Exclusion criteria 
 
Mechanical ventilation (at time of randomization) 
No intention to use pharmacologic thromboprophylaxis* 
Active bleeding 
Risk factors for bleeding 
   Intracranial surgery or stroke within 3 months 
   History of intracranial arteriovenous malformation 
   Cerebral aneurysm or mass lesions of the central nervous system 
   Intracranial malignancy 
   History of bleeding diatheses (e.g., haemophilia) 
   Gastrointestinal bleeding within 3 months 
   Thrombolysis within 7 days 
   Presence of an epidural or spinal catheter 
   Major surgery within 14 days 
   Uncontrolled hypertension (systolic blood pressure >200 mmHg or diastolic blood pressure  
>120 mmHg) 
   Other contraindications to therapeutic anticoagulation 
Platelet count <50 x109/L, international normalized ratio (INR) >2.0, or baseline activated 
partial thromboplastin time (aPTT) >50 seconds 
Hemoglobin <8 g/dL (to minimize the likelihood of transfusion if bleeding were to occur) 
Acute or subacute bacterial endocarditis 
History of heparin induced thrombocytopenia (HIT) or other heparin allergy or 
hypersensitivity  
Current use of dual antiplatelet therapy (e.g., aspirin plus clopidogrel or ticagrelor or 
prasugrel) 
Patients with an independent indication for therapeutic anticoagulation 
Patients in whom imminent demise is anticipated and there is no commitment to active 
intervention  
Anticipated transfer to a non-study site within 72 hours 
Enrollment in other trials related to anticoagulation or antiplatelet therapy 
Refusal of the treating physician 
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Figure 1. Proposed pathophysiologic mechanisms of thrombosis in COVID-19 infection. 
 
 
ACE-2 = angiotensin-converting enzyme II; SARS-CoV-2 = severe acute respiratory syndrome 
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Appendix 1. Study Schedule 
Participants will be given therapeutic-dose parenteral anticoagulation daily, up to 14 days or until 
recovery, defined as hospital discharge or liberation from supplemental oxygen >24 hours 
(provided supplemental oxygen was originally required), whichever comes first. Subjects will be 
followed until hospital discharge, after which time telephone contact will be undertaken to 
ascertain vital status following hospital discharged. (Schedule days refer to post-randomization 





















 +/- 3 days 
 +/- 3 
days 
+/- 7 days 
Consent & Registration X        
Demographics X        
Medical History X        
Weight X        
SOC Vitals documented (SpO2 
and FiO2, heart rate, blood 
pressure, respiratory rate, 
temperature)1 




Hematology bloodwork (SOC)1 X X X X X    
Biochemistry bloodwork (SOC)1 X X X X X    
Troponin (SOC)1 X X X X X    
D-dimer (SOC)1 X X X X X    
Anticoagulant Administration2  X2 X2 X2 X2    
Organ-free support outcome      X   
Primary and secondary outcomes3  X 






Adverse events4  X   




1As per routine standard of care, collected while on therapy (until discharge or up to 14d or 
recovery); record the “worst” value observed during internal since last assessment;  
2 Participants randomized to the investigational arm will receive therapeutic anticoagulation for 
14 days (or until hospital discharge or liberation from supplemental oxygen >24 hours if 
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previously required, whichever comes first) with heparin, with preference for subcutaneous low 
molecular weight heparin (enoxaparin preferred, although dalteparin or tinzaparin are also 
acceptable, as available) if no contraindication is present; alternatively, intravenous 
unfractionated heparin infusion may be used.  
Participants randomized to the control arm will receive usual care, which is anticipated to 
include thromboprophylactic dose anticoagulation according to local practice. 
3All post-discharge follow-up is telephone-/remote.  
4Treatment-related adverse events and concomitant medications assessed only while on therapy. 
  
Abbreviations: SOC=standard of care; SpO2=oxygen saturation; FiO2=fractional inspired 
oxygen; DVT=deep venous thromobosis; PE=pulmonary embolism; MI=myocardial infarction.  
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